Benefits versus risks of latest therapies in multiple sclerosis: A perspective review

Therapeutic Advances in Drug Safety

Volumn 3, Issue 6, 2012, Pages 291-303

  Ontaneda, Daniel ^a   di Capua, Daniela ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

disease modifying agents; multiple sclerosis; risk benefit; safety; toxicity

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FINGOLIMOD; FUMADERM; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; LAQUINIMOD; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ALLERGIC REACTION; APPENDICITIS; BACKACHE; BRADYCARDIA; BUDD CHIARI SYNDROME; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE ACTIVITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FLUSHING; GASTROINTESTINAL TOXICITY; GOODPASTURE SYNDROME; HAIR DISEASE; HERPES SIMPLEX; HUMAN; HYPERTENSION; HYPERTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER; UPPER RESPIRATORY TRACT INFECTION;

EID: 84875489985     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612462599     Document Type: Review

References (80)

1. Ann Marrie R. Rudick R. (2006) Drug Insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol 2: 34–44.
2. Arnold D. Brinar V. Cohen J. Coles A. Confavreux C. Fisher E. (2012) Effect of alemtuzumab vs. rebif(R) on brain MRI measurements: results of CARE-MS I, a Phase 3 Study (S11.006). Neurology 78(Meeting Abstracts 1): S11.006.
3. Biogen Idec (2012) Biogen Idec submits application to FDA for approval of oral BG-12 to treat multiple sclerosis.
4. Bloomgren G. Richman S. Hotermans C. Subramanyam M. Goelz S. Natarajan A. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870–1880.
5. Brinkmann V. (2007) Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84–105.
6. Brinkmann V. Davis M. Heise C. Albert R. Cottens S. Hof R. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453–21457.
7. Calabresi P. Giovannoni G. Confavreux C. Galetta S. Havrdova E. Hutchinson M. (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69: 1391–1403.
8. Chun J. Hartung H. (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91–101.
9. Clifford D. De Luca A. Simpson D. Arendt G. Giovannoni G. Nath A. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438–446.
10. ClinicalTrials.gov (2012a) Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-beta. Available at: ClinicalTrials.Gov.
11. ClinicalTrials.gov (2012b) Phase III Study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis. Available at: ClinicalTrials.Gov.
12. Cohen J. Barkhof F. Comi G. Hartung H. Khatri B. Montalban X. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415.
13. Cohen Chun (2011) Mechanisms of fingolimod–s efficacy and adverse effects in multiple sclerosis. Annals of Neurology 69: 759–777.
14. Cohen J. Twyman C. Arnold D. Coles A. Confavreux C. Fox E. (2012) Efficacy and safety results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): a phase 3 study in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (S01.004). Neurology 78(Meeting Abstracts 1): S01.004.
15. Coles A. Brinar V. Arnold D. Cohen J. Confavreux C. Fox E. (2012a) Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I): a phase 3 study in relapsing–remitting treatment-naive patients (S01.006). Neurology 78(Meeting Abstracts 1): S01.006.
16. Coles A. Compston D. Selmaj K. Lake S. Moran S. Margolin D. for the CAMMS223 Trial Investigators (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801.
17. Coles A. Cox A. Le Page E. Jones J. Trip S. Deans J. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy J Neurol 253: 98–108.
18. Coles A. Fox E. Vladic A. Gazda S. Brinar V. Selmaj K. (2012b) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78: 1069–1078.
19. Collins W. Cohen J. O–Connor P. De Vera A. Zhang-Auberson L. Jin F.J. (2010) Long-term safety of oral fingolimod (fty720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies (P845). In: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) & 15th Annual Conference of Rehabilitation in MS (RIMS), 25 October 2010.
20. Comi G. Jeffery D. Kappos L. Montalban X. Boyko A. Rocca M. (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366: 1000–1009.
21. Comi G. Pulizzi A. Rovaris M. Abramsky O. Arbizu T. Boiko A. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085–2092.
22. Confavreux C. Li D. Freedman M. Truffinet P. Benzerdjeb H. Wang D. (2012) Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 1: 1278–1289.
23. Cossburn M. Pace A. Jones J. Ali R. Ingram G. Baker K. (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort Neurology 77: 573–579.
24. Costelloe L. Jones J. Coles A. (2012) Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Review of Neurotherapeutics 12: 335–341.
25. DiMarco J. O–Connor P. Cohen J. (2010) First-dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS) (P830). Mult Scler 16(Suppl 10): S290.
26. Espinosa P. Berger J. (2011) Delayed fingolimod-associated asystole. Mult Scler 17: 1387–1389.
27. European Medicines Agency (2012) European Medicines agency starts review of Gilenya (fingolimod), Press release, 20 January 2012.
28. Food and Drug Administration (2012) FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).
29. Fox E. Sullivan H. Gazda S. Mayer L. O–Donnell L. Melia K. (2012a) A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 19: 307–311.
30. Fox R. Miller D. Phillips J. Kita M. Hutchinson M. Havrdova E. (2012b) Clinical efficacy of BG-12 in relapsing–remitting multiple sclerosis (RRMS): data from the phase 3 CONFIRM Study (S01.003). Neurology 78(Meeting Abstracts 1): S01.003.
31. Fox R. Rudick R. (2012) Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 78: 436–437.
32. Genzyme Corporation (2011) Genzyme Reports Top-Line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis.
33. Genzyme Corporation (2012) Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (Teriflunomide) in Relapsing Multiple Sclerosis.
34. Gold R. Kappos L. Bar-Or A. (2011) Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. In: Program and Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), Amsterdam, the Netherlands, 19–22 October 2011.
35. Goodin D. (2004) Disease-modifying therapy in MS: a critical review of the literature. Part II: assessing efficacy and dose-response. J Neurol 251(Suppl 5): v50–v56.
36. Gorelik L. Lerner M. Bixler S. Crossman M. Schlain B. Simon K. (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295–303.
37. Greene S. Watanabe K. Braatz-Trulson J. Lou L. (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50: 861–867.
38. Hirst C. Pace A. Pickersgill T. Jones R. McLean B. Zajicek J. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis J Neurol 255: 231–238.
39. Hla T. (2003) Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 47: 401–407.
40. Hoefnagel J. Thio H. Willemze R. Bouwes Bavinck J. (2003) Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149: 363–369.
41. Hoitsma A. Woodle E. Abramowicz D. Proot P. Vanrenterghem Y. for the FTY720 Phase II Transplant Study Group (2011) FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant 26: 3802–3805.
42. Ishii I. Fukushima N. Ye X. Chun J. (2004) Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73: 321–354.
43. Jones J. Anderson J. Phuah C. Fox E. Selmaj K. Margolin D. (2010) Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity Brain 133: 2232–2247.
44. Jones J. Coles A. (2008) Campath-1H treatment of multiple sclerosis Neurodegener Dis 5: 27–31.
45. Jonsson S. Andersson G. Fex T. Fristedt T. Hedlund G. Jansson K. (2004) Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 47: 2075–2088.
46. Kala M. Miravalle A. Vollmer T. (2011) Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol 235: 9–17.
47. Kappos L. Radue E. O–Connor P. Polman C. Hohlfeld R. Calabresi P. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
48. Kieseier B. (2011) The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 25: 491–502.
49. Kleinschmidt-DeMasters B. Tyler K. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369–374.
50. Klotz L. Meuth S. Wiendl H. (2012) Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 142: 25–30.
51. Langer-Gould A. Atlas S. Green A. Bollen A. Pelletier D. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375–381.
52. Linker R. Lee D. Ryan S. Van Dam A. Conrad R. Bista P. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134: 678–692.
53. Lutterotti A. Martin R. (2008) Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 7: 538–547.
54. Marriott J. O–Connor P. (2011) Definitions of breakthrough disease and second-line agents. Neurol Clin 29: 411–422.
55. Martinelli V. Radaelli M. Straffi L. Rodegher M. Comi G. (2009) Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 30(Suppl 2): S167–S170.
56. Miller A. Spada V. Beerkircher D. Kreitman R. (2008) Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing–remitting multiple sclerosis. Mult Scler 14: 494–499.
57. Monaco M. Major E. (2012) The link between VLA-4 and JC virus reactivation. Expert Rev Clin Immunol 8: 63–72.
58. O–Connor P. Li D. Freedman M. Bar-Or A. Rice G. Confavreux C. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894–900.
59. O–Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. Olsson T. (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365: 1293–1303.
60. Ontaneda D. Cohen J. (2011) Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Rev Clin Pharmacol 4: 567–570.
61. Phillips J.T. Fox R. Miller D. Kita M. Hutchinson M. Havrdova E. (2012) Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis (RRMS): analyses from the CONFIRM study (S41.005). Neurology 78(Meeting Abstracts 1): S41.005.
62. Polman C. Barkhof F. Sandberg-Wollheim M. Linde A. Nordle O. Nederman T. (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64: 987–991.
63. Polman C. O–Connor P. Havrdova E. Hutchinson M. Kappos L. Miller D. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.
64. Rudick R. Polman C. (2009) Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurology 8: 545–559.
65. Rudick R. Sandrock A. (2004) Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4: 571–580.
66. Rudick R. Stuart W. Calabresi P. Confavreux C. Galetta S. Radue E. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911–923.
67. Salvadori M. Budde K. Charpentier B. Klempnauer J. Nashan B. Pallardo L. (2006) FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 6: 2912–2921.
68. Selmaj K. Arnold D. Brinar V. Cohen J. Coles A. Confavreux C. (2012) Incidence of autoimmunity in a phase 3 trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006). Neurology 78(Meeting Abstracts 1): S41.006.
69. Sorensen P. Bertolotto A. Edan G. Giovannoni G. Gold R. Havrdova E. (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18: 143–152.
70. Tan I. Lycklama a Nijeholt G. Polman C. Ader H. Barkhof F. (2000) Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials Mult Scler 6: 99–104.
71. Tedesco-Silva H. Szakaly P. Shoker A. Sommerer C. Yoshimura N. Schena F. (2007) FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 84: 885–892.
72. Teva Pharmaceutical Industries (2011) TEVA - Investor Relations (IR) - News Release.
73. Thone J. Ellrichmann G. Seubert S. Peruga I. Lee D. Conrad R. (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180: 267–274.
74. Van Assche G. Van Ranst M. Sciot R. Dubois B. Vermeire S. Noman M. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn–s disease. N Engl J Med 353: 362–368.
75. Vermersch P. Kappos L. Gold R. Foley J. Olsson T. Cadavid D. (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76: 1697–1704.
76. Vollmer T. Comi G. Sorensen P. Arnold D. Filippi M. Statinova O. (2012) Clinical efficacy of laquinimod for the treatment of multiple sclerosis; pooled analyses from the ALLEGRO and BRAVO phase III trials (S01.007). Neurology 78(Meeting Abstracts 1): S01.007.
77. Xu X. Blinder L. Shen J. Gong H. Finnegan A. Williams J. (1997) In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 159: 167–174.
78. Yang J. Xu L. Xiao B. Hedlund G. Link H. (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 156: 3–9.
79. Yousry T. Major E. Ryschkewitsch C. Fahle G. Fischer S. Hou J. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924–933.
80. Zeyda M. Poglitsch M. Geyeregger R. Smolen J. Zlabinger G. Hörl W. (2005) Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52: 2730–2739.